Fractioned radiotherapy safe and effective for optic nerve sheath meningiomas

Article

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas.

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas, according to Silas Wang, MD.

"Optic nerve sheath meningiomas are rare and constitute only 1.3% of meningiomas," Dr. Wang said at the American Academy of Ophthalmology annual meeting.

Dr. Wang and colleagues from Yale University School of Medicine, New Haven, CT, used primary conformal fractioned radiotherapy (45.00 to 54.00 Gy in 25 to 29 fractions) in 16 patients, 14 of whom were women (average age, 45.1 years). Ninety-four percent of the patients had had vision loss. The mean follow-up was 45 months.

Dr. Wang reported that the visual acuity stabilized in 11 patients and the final visual acuity was 20/20 or better in nine patients. One patient had a progress decline in visual acuity to hand motion vision. There was an improvement of two or more lines of visual acuity in four patients. The visual fields improved by a mean of 3.2 decibels. In addition, the color vision stabilized. The delayed complications of the treatment included dry eye and hormonal changes. The results that Dr. Wang reported are consistent with those of a previous study.

"Conformal fractionated radiotherapy is effective in mild visual acuity loss," he concluded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.